Specialised Therapeutics

What Specialised Therapeutics does

Specialised Therapeutics (ST) is an independent specialty pharmaceutical company founded in 2007 and headquartered in Singapore. The company commercialises novel therapies under exclusive distribution and licensing agreements with international pharmaceutical developers, serving patients in Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, Vietnam, and the Philippines. Its core activity is not drug discovery but rather the regulatory navigation (Australia's TGA via Priority Review and Project Orbis; Singapore's HSA), reimbursement listing (Australia's PBS, named-patient and Special Access Schemes), field sales, medical affairs, and supply chain operations required to bring approved specialty medicines to market across the region.

ST's product portfolio spans oncology (ZEPZELCA/lurbinectedin, NERLYNX/neratinib, ABRAXANE/nab-paclitaxel, ICLUSIG/ponatinib, PEMAZYRE/pemigatinib, Zynyz/retifanlimab), haematology (MINJUVI/tafasitamab, NIKTIMVO/axatilimab), endocrinology (YORVIPATH/palopegteriparatide, SKYTROFA/lonapegsomatropin using Ascendis Pharma's TransCon prodrug platform), ophthalmology (ILUVIEN/fluocinolone acetonide), and supportive care (AKYNZEO, GELCLAIR). The technologies commercialised are exclusively third-party—ranging from monoclonal antibodies (CD19-targeted tafasitamab, CSF-1R-blocking axatilimab) to kinase inhibitors and prodrug sustained-release platforms—with ST holding no proprietary R&D pipeline of its own.

The business model is distribution-and-licensing: ST signs exclusive territorial agreements with drug developers (18 disclosed partners including Incyte, Ascendis Pharma, Puma Biotechnology, Helsinn, PharmaMar, Alimera Sciences, ARIAD, Bristol-Myers Squibb, Deciphera, and Akeso), assumes responsibility for local regulatory approvals and PBS/HSA submissions, deploys field sales representatives and oncology/haematology medical liaisons to engage healthcare professionals and hospitals, and earns revenue through product sales. Pricing is administered via government reimbursement schemes, with most products listed or pursuing PBS listings. The company is privately held with no disclosed external investors, no parent company, and no disclosed revenue, headcount, or funding figures; CEO Carlo Montagner has led the company in its independent posture since founding.

Name

Specialised Therapeutics

Legal name

Specialised Therapeutics

Website

https://stabiopharma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Specialised Therapeutics is an independent specialty pharmaceutical company that commercialises novel third-party therapies under exclusive distribution agreements across Australia, New Zealand, and Southeast Asia, serving patients with rare cancers, haematological conditions, endocrinology, and ophthalmology needs via PBS and field sales.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Specialty pharmaceuticals
• Oncology therapies
• Rare disease drugs
• Biopharmaceutical distribution
• Hematology treatments

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Distribution and Commercialisation: Specialised Therapeutics generates revenue by commercialising specialty pharmaceutical products under exclusive distribution agreements with international pharmaceutical companies. The company obtains regulatory approvals (TGA, HSA) and negotiates reimbursement listings (PBS) to distribute therapies in Australia, New Zealand, Singapore, and Southeast Asia.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Specialised Therapeutics is an independent specialty biopharmaceutical company that in-licenses and commercialises specialty pharmaceutical products for the Australia, New Zealand, and Southeast Asia region through exclusive distribution agreements with 18 international pharmaceutical companies. Its portfolio addresses rare cancers, rare diseases, oncology, hematology, and endocrinology, and includes both innovative therapeutics and supportive care products.

Product overview

Specialised Therapeutics is a specialty pharmaceutical company that commercialises a broad portfolio of novel therapies across multiple therapeutic areas including oncology, haematology, CNS, neurology, endocrinology, ophthalmology, and supportive care. The company operates through exclusive partnering agreements with international pharmaceutical companies (primarily Incyte, Ascendis Pharma, Puma Biotechnology, Helsinn, and others) to register and commercialise specialty medicines in Australia, New Zealand, and Southeast Asia. The product portfolio includes targeted cancer therapies (ZEPZELCA, NERLYNX, ABRAXANE, ICLUSIG, PEMAZYRE), haematology treatments (MINJUVI, NIKTIMVO), endocrine therapies (YORVIPATH, SKYTROFA), supportive care products (AKYNZEO, GELCLAIR), and ophthalmology treatments (ILUVIEN). The company focuses on bringing innovative medicines to patients with unmet medical needs through regulatory navigation, reimbursement, and commercialisation in the Asia-Pacific region.

Differentiator

Problem solved

Functional benefit

Brands

• ST: Common abbreviation used for Specialised Therapeutics in press releases and company communications.

Products and services

• NIKTIMVO

Quantifiable outcome

• 74% overall response rate in AGAVE-201 trial for NIKTIMVO in chronic GVHD
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

14 partnerships are on record, tiered core and secondary.

• Puma BiotechnologycoreChannel Partner/ Reseller/ Distributor · 1 January 2026ST makes NERLYNX (neratinib) available in Thailand under exclusive license from Puma Biotechnology, Inc. (Nasdaq: PBYI).
• IncytecoreChannel Partner/ Reseller/ Distributor · 11 June 2025In June 2025, ST expanded its existing partnership with Incyte to include axatilimab (Niktimvo) and retifanlimab (Zynyz), in addition to existing products Minjuvi (tafasitamab) and Pemazyre (pemigatinib). The agreement covers Australia, New Zealand and Singapore with an option to add further countries in Asia-Pacific. Incyte is responsible for development, manufacture and supply while ST handles regulatory, distribution and local marketing activities.
• Ascendis PharmacoreChannel Partner/ Reseller/ Distributor · 21 February 2025ST holds an exclusive distribution agreement with Ascendis Pharma A/S covering Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam for YORVIPATH (palopegteriparatide) and SKYTROFA (lonapegsomatropin).
• IncytecoreChannel Partner/ Reseller/ Distributor · 1 January 2021ST entered into an exclusive distribution agreement with Incyte in 2021 to commercialise Minjuvi (tafasitamab) in Australia, New Zealand and Singapore.
• HelsinnsecondaryChannel Partner/ Reseller/ Distributor · 8 May 2015ST partnered with Helsinn Group to commercialise AKYNZEO (netupitant/palonosetron) in Australia for the prevention of chemotherapy-induced nausea and vomiting.
• PharmamarsecondaryChannel Partner/ Reseller/ DistributorPartnership to commercialise Zepzelca (lurbinectedin) for small cell lung cancer.
• Puma BiotechnologysecondaryChannel Partner/ Reseller/ DistributorPartnership for NERLYNX (neratinib) for HER2+ breast cancer.
• Alimera SciencessecondaryChannel Partner/ Reseller/ DistributorPartnership to distribute ILUVIEN (fluocinolone acetonide) for diabetic macular oedema in Australia and New Zealand.
• ARIAD PharmaceuticalssecondaryChannel Partner/ Reseller/ DistributorPartnership to commercialise ICLUSIG (ponatinib) for chronic myeloid leukaemia in Australia.
• OnconovasecondaryChannel Partner/ Reseller/ DistributorPartnership for oncology therapies.
• Bristol-Myers SquibbsecondaryChannel Partner/ Reseller/ DistributorPartnership for oncology products.
• Canaria BiosecondaryChannel Partner/ Reseller/ DistributorPartnership for ovarian cancer therapy.
• TreewaysecondaryChannel Partner/ Reseller/ DistributorPartnership for rare disease therapies.
• AkesosecondaryChannel Partner/ Reseller/ DistributorPartnership for biopharmaceutical products.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Mundipharma: Singapore-headquartered, family-owned independent specialty pharma with a network model across Asia-Pacific and other regions; closely mirrors ST's structure of commercialising partnered assets rather than developing proprietary R&D.
• Zuellig Pharma: Asia-Pacific pharmaceutical distribution and commercialisation specialist partnering with global manufacturers to bring specialty therapies to SE Asia — directly comparable distribution-led, multi-country model.
• DKSH Holding (Healthcare): Swiss-listed market-expansion services group that provides regulatory, distribution and commercialisation for pharma clients across Asia-Pacific; ST operates a similar specialist vertical on a more focused therapeutic base.
• Clinigen Group: UK-listed specialty pharma access and distribution platform providing unlicensed and licensed medicines globally; comparable asset-light, partnership-driven model targeting rare/specialty therapies.
• Norgine: European specialty pharma focused on gastroenterology, oncology supportive care and rare diseases with established Asia-Pacific commercialisation partnerships; comparable specialty-pharma positioning and in-licensed-portfolio model.

Broad incumbents

• Aspen Pharmacare: South African specialty/generics pharma with a substantial ANZ and emerging-market footprint via portfolio of in-licensed and acquired assets; comparable regional commercial-platform play but at far larger scale.
• Hikma Pharmaceuticals: MENA-headquartered specialty/generics pharma with global in-licensing and branded distribution across multiple regions; broad incumbent operating a similar partner-led commercial model.
• Menarini Group (Asia-Pacific): Privately-held Italian pharma group with a growing Asia-Pacific presence distributing in-licensed specialty products; relevant peer for the in-licensed/regional-distribution model though at larger scale.
• Servier (Asia-Pacific): Independent French specialty pharma with an active oncology and rare-disease portfolio distributed through regional partners across APAC; comparable therapeutic focus though operates its own sales infrastructure in some markets.

Emerging players

• Sojournix Pharmaceuticals: An emerging US-listed specialty pharma focused on oncology and rare endocrinology with Asia-Pacific ambitions via partners; representative emerging peer that, like ST, relies on partner-driven specialty launches in niche indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/specialisedtherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Specialised Therapeutics